It is possible to prevent colic in healthy infants

STOCKHOLM – (BUSINESS WIRE) – A study of 468 healthy newborns shows that babies who received the probiotic Lactobacillus reuteri Protectis cried less than half the time of children who were given a placebo. Children who received Lactobacillus reuteri Protectis also showed markedly less daily regurgitation and suffered less constipation compared to babies in the placebo group. “This is the first study to demonstrate the prophylactic use of a specific strain (L. reuteri Protectis) in a disease such as functional digestive disorders (colic, regurgitation and constipation).” In addition, it is also the first evaluation of the cost relationship -benefit of a probiotic treatment for infants and shows that L. reuteri Protectis is useful for the family and for society, “said Dr. Flavia Indrio, a professional in the Department of Pediatrics at the University of Bari, Italy. Less crying, less constipation and less regurgitation … The intervention occurred from the first days of life. After one month of using Lactobacillus reuteri Protectis drops, children cried, per day, less than half the time as infants who received a placebo (45 minutes vs. 96 minutes). The significant difference between the groups persisted until the end of the intervention, which spanned three months. Infants in the group that received Lactobacillus reuteri Protectis also had better intestinal motility, resulting in much more daily bowel movements and less regurgitation compared to infants in the placebo group.


… Less costs for the family and the community

Colic, regurgitation and constipation not only cause pain to the baby. These situations often result in numerous visits to the pediatrician and even hospitalization and use of drugs, in addition to causing anxiety and loss of work days of parents. Calculating only the direct costs, the researchers concluded that with the use of Lactobacillus reuteri Protectis each family could save 88 euros. In addition, the community saved 104 euros per child. “This study is innovative because it shows that the BioGaia product should be given to all children from birth, not only to lessen the suffering of babies and parents, but also to reduce family and social costs. This study will be extremely important for the future development of the segment of BioGaia specialized in babies, “said Peter Rothschild, president of BioGaia. The study was published in the prestigious JAMA medical journal on January 13, 2014. For more information on colic, constipation, regurgitation, study details and to read an interview with Dr. Indrio, visit the attached links. Lactobacillus reuteri Protectis in drop format is marketed in Spain by Casen Fleet Laboratories. BioGaia is a company specialized in medical care, which develops, introduces to the market and sells products with documented health benefits. The products are based, mainly, on Lactobacillus reuteri lactic acid bacteria that has probiotic effects, which improve health. The class B shares of the parent company, BioGaia AB (STO: BIOG-B), are listed on the list of mid-cap companies of the NASDAQ OMX Nordic Exchange in Stockholm. www.biogaia.com